NCT05445310View on ClinicalTrials.gov

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

August 6, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Furmonertinib

Furmonertinib 80mg/d

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hopital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER